Anthony Cheung
Founder at ENGENE HOLDINGS INC.
Net worth: 904 254 $ as of 30/05/2024
Anthony Cheung active positions
Companies | Position | Start | End |
---|---|---|---|
ENGENE HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 23/04/2023 | - |
Founder | 23/04/2023 | - | |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Director/Board Member | - | - |
Chief Tech/Sci/R&D Officer | 15/07/2018 | - | |
Founder | - | - | |
Chief Executive Officer | 24/10/2011 | 15/07/2018 | |
President | 24/10/2011 | 15/07/2018 | |
Corporate Secretary | 31/12/1998 | 24/05/2011 |
Career history of Anthony Cheung
Training of Anthony Cheung
University of British Columbia | Undergraduate Degree |
Tulane University School of Medicine | Doctorate Degree |
Statistics
International
Canada | 4 |
United States | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ENGENE HOLDINGS INC. | Health Technology |
Private companies | 1 |
---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Anthony Cheung
- Experience